RU2007147959A - Органические соединения - Google Patents
Органические соединения Download PDFInfo
- Publication number
- RU2007147959A RU2007147959A RU2007147959/04A RU2007147959A RU2007147959A RU 2007147959 A RU2007147959 A RU 2007147959A RU 2007147959/04 A RU2007147959/04 A RU 2007147959/04A RU 2007147959 A RU2007147959 A RU 2007147959A RU 2007147959 A RU2007147959 A RU 2007147959A
- Authority
- RU
- Russia
- Prior art keywords
- oxo
- phenyl
- dihydropyridin
- alkyl
- methylaminopropionamide
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- -1 —CHCH3 Chemical group 0.000 claims abstract 62
- 125000000217 alkyl group Chemical group 0.000 claims abstract 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 30
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract 7
- 150000002367 halogens Chemical class 0.000 claims abstract 7
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 4
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 2
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229940080818 propionamide Drugs 0.000 claims 15
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 13
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 12
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 11
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- QRKPPWPLSQRGSU-UHFFFAOYSA-N diazepine-1-carboxylic acid Chemical compound OC(=O)N1C=CC=CC=N1 QRKPPWPLSQRGSU-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- DSWQOVAEVMDMLK-NRFANRHFSA-N (2s)-n-[1-[2-(2,2-diphenylethylamino)-2-oxoethyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CNC(=O)CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 DSWQOVAEVMDMLK-NRFANRHFSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- BJNVAQKPBNDERE-FQEVSTJZSA-N (2S)-2-(ethylamino)-N-[1-[[3-(4-fluorobenzoyl)phenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NCC)=CC=C1C1=CC=CC=C1 BJNVAQKPBNDERE-FQEVSTJZSA-N 0.000 claims 1
- UKRZDZDSVAEZIB-IBGZPJMESA-N (2s)-2-(ethylamino)-n-[1-[3-(4-fluoroanilino)benzoyl]-2-oxo-6-phenylpyridin-3-yl]propanamide Chemical compound C=1C=CC(NC=2C=CC(F)=CC=2)=CC=1C(=O)N1C(=O)C(NC(=O)[C@H](C)NCC)=CC=C1C1=CC=CC=C1 UKRZDZDSVAEZIB-IBGZPJMESA-N 0.000 claims 1
- HGZJYVOSGZBPLA-FQEVSTJZSA-N (2s)-2-(ethylamino)-n-[1-[[3-(4-fluoroanilino)phenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]propanamide Chemical compound C=1C=CC(NC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NCC)=CC=C1C1=CC=CC=C1 HGZJYVOSGZBPLA-FQEVSTJZSA-N 0.000 claims 1
- DRIZXPSWQXTWQI-FQEVSTJZSA-N (2s)-2-(methylamino)-n-[2-oxo-1-[(3-phenoxyphenyl)methyl]-6-phenylpyridin-3-yl]propanamide Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 DRIZXPSWQXTWQI-FQEVSTJZSA-N 0.000 claims 1
- UFSQVPXRLDGSJZ-NRFANRHFSA-N (2s)-n-[1-[2-(1,3-dihydroisoindol-2-yl)-2-oxoethyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)butanamide Chemical compound C1C2=CC=CC=C2CN1C(=O)CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 UFSQVPXRLDGSJZ-NRFANRHFSA-N 0.000 claims 1
- MKVKWNPWVAMZHR-KRWDZBQOSA-N (2s)-n-[1-[2-(1,3-dihydroisoindol-2-yl)-2-oxoethyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C1C2=CC=CC=C2CN1C(=O)CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 MKVKWNPWVAMZHR-KRWDZBQOSA-N 0.000 claims 1
- ZUFVEZUNZINJOH-QHCPKHFHSA-N (2s)-n-[1-[2-(2,3-dihydro-1h-inden-2-yloxy)ethyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)butanamide Chemical compound C1C2=CC=CC=C2CC1OCCN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 ZUFVEZUNZINJOH-QHCPKHFHSA-N 0.000 claims 1
- JMOAVXGTFIDXSI-SFHVURJKSA-N (2s)-n-[1-[2-(2,3-dihydro-1h-inden-2-yloxy)ethyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C1C2=CC=CC=C2CC1OCCN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 JMOAVXGTFIDXSI-SFHVURJKSA-N 0.000 claims 1
- RBYJKUIGAQLBMH-INIZCTEOSA-N (2s)-n-[1-[2-[(4-fluorophenyl)methylamino]-2-oxoethyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=C(F)C=CC=1CNC(=O)CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 RBYJKUIGAQLBMH-INIZCTEOSA-N 0.000 claims 1
- GTOMYMCZBPZBLS-BXXZMZEQSA-N (2s)-n-[1-[2-[ethyl(1,2,3,4-tetrahydronaphthalen-1-yl)amino]-2-oxoethyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)butanamide Chemical compound C1CCC2=CC=CC=C2C1N(CC)C(=O)CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=C(F)C=C1 GTOMYMCZBPZBLS-BXXZMZEQSA-N 0.000 claims 1
- NHSQWHIHHMEKPI-SXMXNQBWSA-N (2s)-n-[1-[2-[ethyl(1,2,3,4-tetrahydronaphthalen-1-yl)amino]-2-oxoethyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C1CCC2=CC=CC=C2C1N(CC)C(=O)CN(C(C(NC(=O)[C@H](C)NC)=CC=1)=O)C=1C1=CC=C(F)C=C1 NHSQWHIHHMEKPI-SXMXNQBWSA-N 0.000 claims 1
- IVIBCTPZKXRZTA-SXMXNQBWSA-N (2s)-n-[1-[2-[ethyl(1,2,3,4-tetrahydronaphthalen-1-yl)amino]acetyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C1CCC2=CC=CC=C2C1N(CC)CC(=O)N(C(C(NC(=O)[C@H](C)NC)=CC=1)=O)C=1C1=CC=C(F)C=C1 IVIBCTPZKXRZTA-SXMXNQBWSA-N 0.000 claims 1
- CMESKYBIBNHDTA-SVQMELKDSA-N (2s)-n-[1-[2-[ethyl(1,2,3,4-tetrahydronaphthalen-1-yl)amino]ethyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C1CCC2=CC=CC=C2C1N(CC)CCN(C(C(NC(=O)[C@H](C)NC)=CC=1)=O)C=1C1=CC=C(F)C=C1 CMESKYBIBNHDTA-SVQMELKDSA-N 0.000 claims 1
- YTUMXTFLWANXIS-QFIPXVFZSA-N (2s)-n-[1-[2-[ethyl-[(4-fluorophenyl)methyl]amino]-2-oxoethyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=C(F)C=CC=1CN(CC)C(=O)CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=C(F)C=C1 YTUMXTFLWANXIS-QFIPXVFZSA-N 0.000 claims 1
- RJJDVYGXIQJCBR-KRWDZBQOSA-N (2s)-n-[1-[2-[ethyl-[(4-fluorophenyl)methyl]amino]-2-oxoethyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=C(F)C=CC=1C1=CC=C(NC(=O)[C@H](C)NC)C(=O)N1CC(=O)N(CC)CC1=CC=C(F)C=C1 RJJDVYGXIQJCBR-KRWDZBQOSA-N 0.000 claims 1
- FWYIGTLXAWSBBC-SFHVURJKSA-N (2s)-n-[1-[2-[ethyl-[(4-fluorophenyl)methyl]amino]ethyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=C(F)C=CC=1CN(CC)CCN(C(C(NC(=O)[C@H](C)NC)=CC=1)=O)C=1C1=CC=C(F)C=C1 FWYIGTLXAWSBBC-SFHVURJKSA-N 0.000 claims 1
- PVVAIJHFANOEDG-DEOSSOPVSA-N (2s)-n-[1-[3-(4-fluorobenzoyl)benzoyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=CC(C(=O)C=2C=CC(F)=CC=2)=CC=1C(=O)N1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 PVVAIJHFANOEDG-DEOSSOPVSA-N 0.000 claims 1
- JTPXRKBISRDJAM-SFHVURJKSA-N (2s)-n-[1-[3-(4-fluorobenzoyl)benzoyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC(F)=CC=2)=CC=1C(=O)N1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 JTPXRKBISRDJAM-SFHVURJKSA-N 0.000 claims 1
- DXKGERZQZOHAAR-SFHVURJKSA-N (2s)-n-[1-[3-(4-fluorophenoxy)benzoyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(OC=2C=CC(F)=CC=2)=CC=1C(=O)N1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 DXKGERZQZOHAAR-SFHVURJKSA-N 0.000 claims 1
- XOUBNNDYHJEUDL-SFHVURJKSA-N (2s)-n-[1-[3-(4-fluorophenyl)sulfanylbenzoyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(SC=2C=CC(F)=CC=2)=CC=1C(=O)N1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 XOUBNNDYHJEUDL-SFHVURJKSA-N 0.000 claims 1
- VMSPUECDJZCSTJ-SFHVURJKSA-N (2s)-n-[1-[3-(4-fluorophenyl)sulfonylbenzoyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(S(=O)(=O)C=2C=CC(F)=CC=2)=CC=1C(=O)N1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 VMSPUECDJZCSTJ-SFHVURJKSA-N 0.000 claims 1
- IXGRPXIBRPJNKB-VWLOTQADSA-N (2s)-n-[1-[[3-(4-fluoroanilino)phenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=CC(NC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 IXGRPXIBRPJNKB-VWLOTQADSA-N 0.000 claims 1
- ZAKUXESMRJSKER-SFHVURJKSA-N (2s)-n-[1-[[3-(4-fluoroanilino)phenyl]methyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(NC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 ZAKUXESMRJSKER-SFHVURJKSA-N 0.000 claims 1
- CUFUGIFIDDHNAY-VWLOTQADSA-N (2s)-n-[1-[[3-(4-fluorobenzoyl)phenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=CC(C(=O)C=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 CUFUGIFIDDHNAY-VWLOTQADSA-N 0.000 claims 1
- XTWORBQLYLGZOJ-SFHVURJKSA-N (2s)-n-[1-[[3-(4-fluorobenzoyl)phenyl]methyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 XTWORBQLYLGZOJ-SFHVURJKSA-N 0.000 claims 1
- VLFJFYXYZQIBCT-VWLOTQADSA-N (2s)-n-[1-[[3-(4-fluorophenoxy)phenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=CC(OC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 VLFJFYXYZQIBCT-VWLOTQADSA-N 0.000 claims 1
- VVFYZPVNTDMBKC-IBGZPJMESA-N (2s)-n-[1-[[3-(4-fluorophenoxy)phenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(OC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 VVFYZPVNTDMBKC-IBGZPJMESA-N 0.000 claims 1
- BCEYTJDBPKAJAY-VWLOTQADSA-N (2s)-n-[1-[[3-(4-fluorophenoxy)phenyl]methyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=CC(OC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=C(F)C=C1 BCEYTJDBPKAJAY-VWLOTQADSA-N 0.000 claims 1
- NXVFMDFTMJCMRW-SFHVURJKSA-N (2s)-n-[1-[[3-(4-fluorophenoxy)phenyl]methyl]-6-(4-fluorophenyl)-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(OC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 NXVFMDFTMJCMRW-SFHVURJKSA-N 0.000 claims 1
- DMVWTUFMNOJQJN-IBGZPJMESA-N (2s)-n-[1-[[3-(4-fluorophenyl)sulfanylphenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(SC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 DMVWTUFMNOJQJN-IBGZPJMESA-N 0.000 claims 1
- AYNHTWSWUQVRMQ-VWLOTQADSA-N (2s)-n-[1-[[3-(4-fluorophenyl)sulfonylphenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=CC(S(=O)(=O)C=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 AYNHTWSWUQVRMQ-VWLOTQADSA-N 0.000 claims 1
- MEZFCJCDQYQNCR-IBGZPJMESA-N (2s)-n-[1-[[3-(4-fluorophenyl)sulfonylphenyl]methyl]-2-oxo-6-phenylpyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(S(=O)(=O)C=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=CC=C1 MEZFCJCDQYQNCR-IBGZPJMESA-N 0.000 claims 1
- PAFBFPBLROZSBY-FQEVSTJZSA-N (2s)-n-[6-(4-fluorophenyl)-1-[2-[(4-fluorophenyl)methylamino]-2-oxoethyl]-2-oxopyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=C(F)C=CC=1CNC(=O)CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=C(F)C=C1 PAFBFPBLROZSBY-FQEVSTJZSA-N 0.000 claims 1
- VOMHICCAKBNGMC-HNNXBMFYSA-N (2s)-n-[6-(4-fluorophenyl)-1-[2-[(4-fluorophenyl)methylamino]-2-oxoethyl]-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=C(F)C=CC=1CNC(=O)CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 VOMHICCAKBNGMC-HNNXBMFYSA-N 0.000 claims 1
- FACGLOMYPPLPLQ-SFHVURJKSA-N (2s)-n-[6-(4-fluorophenyl)-1-[[3-(4-fluorophenyl)sulfanylphenyl]methyl]-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(SC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 FACGLOMYPPLPLQ-SFHVURJKSA-N 0.000 claims 1
- NKPVOQWPPJVFKQ-VWLOTQADSA-N (2s)-n-[6-(4-fluorophenyl)-1-[[3-(4-fluorophenyl)sulfonylphenyl]methyl]-2-oxopyridin-3-yl]-2-(methylamino)butanamide Chemical compound C=1C=CC(S(=O)(=O)C=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=C(F)C=C1 NKPVOQWPPJVFKQ-VWLOTQADSA-N 0.000 claims 1
- FKOMSOIJGLVTLS-SFHVURJKSA-N (2s)-n-[6-(4-fluorophenyl)-1-[[3-(4-fluorophenyl)sulfonylphenyl]methyl]-2-oxopyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC(S(=O)(=O)C=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 FKOMSOIJGLVTLS-SFHVURJKSA-N 0.000 claims 1
- ZKHAGSIZBVLPDA-NQCNTLBGSA-N (2s)-n-[6-(4-fluorophenyl)-2-oxo-1-[2-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl]pyridin-3-yl]-2-(methylamino)butanamide Chemical compound C1CCC2=CC=CC=C2C1NC(=O)CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=C(F)C=C1 ZKHAGSIZBVLPDA-NQCNTLBGSA-N 0.000 claims 1
- OUVQBOSBRWVKPE-LBOXEOMUSA-N (2s)-n-[6-(4-fluorophenyl)-2-oxo-1-[2-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl]pyridin-3-yl]-2-(methylamino)propanamide Chemical compound C1CCC2=CC=CC=C2C1NC(=O)CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1C1=CC=C(F)C=C1 OUVQBOSBRWVKPE-LBOXEOMUSA-N 0.000 claims 1
- HPDYXFRQDGGEIU-IBGZPJMESA-N (2s)-n-[6-benzyl-2-oxo-1-[2-oxo-2-(2-phenylethylamino)ethyl]pyridin-3-yl]-2-(methylamino)propanamide Chemical compound C=1C=CC=CC=1CCNC(=O)CN1C(=O)C(NC(=O)[C@H](C)NC)=CC=C1CC1=CC=CC=C1 HPDYXFRQDGGEIU-IBGZPJMESA-N 0.000 claims 1
- RMJZRXGIWODYQW-KRWDZBQOSA-N (2s)-n-[6-butyl-2-oxo-1-[2-oxo-2-(2-phenylethylamino)ethyl]pyridin-3-yl]-2-(methylamino)propanamide Chemical compound CCCCC1=CC=C(NC(=O)[C@H](C)NC)C(=O)N1CC(=O)NCCC1=CC=CC=C1 RMJZRXGIWODYQW-KRWDZBQOSA-N 0.000 claims 1
- HFACYWDPMNWMIW-UHFFFAOYSA-N 2-cyclohexylethanamine Chemical compound NCCC1CCCCC1 HFACYWDPMNWMIW-UHFFFAOYSA-N 0.000 claims 1
- DRIIALWPEHYWHX-UHFFFAOYSA-N C1(=CC=CC=C1)CCNC(=O)N1N=CC=CC=C1 Chemical compound C1(=CC=CC=C1)CCNC(=O)N1N=CC=CC=C1 DRIIALWPEHYWHX-UHFFFAOYSA-N 0.000 claims 1
- HWVYFJFAWRNQPE-SANMLTNESA-N C=1C=CC(NCC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 Chemical compound C=1C=CC(NCC=2C=CC(F)=CC=2)=CC=1CN1C(=O)C(NC(=O)[C@@H](NC)CC)=CC=C1C1=CC=CC=C1 HWVYFJFAWRNQPE-SANMLTNESA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- BXQUHCKQEAELBU-MSYFUGIWSA-N n-[(4s,7s)-6,10-dioxo-4-(2-phenylethylsulfanylmethyl)-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepin-7-yl]-2-(methylamino)propanamide Chemical compound C([C@@H]1CCCN2C(=O)CC[C@@H](C(N21)=O)NC(=O)C(C)NC)SCCC1=CC=CC=C1 BXQUHCKQEAELBU-MSYFUGIWSA-N 0.000 claims 1
- SVUWENNYDNCSJC-PDDQFZCSSA-N n-[(4s,7s)-6,10-dioxo-4-(2-phenylethylsulfinylmethyl)-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepin-7-yl]-2-(methylamino)butanamide Chemical compound C([C@@H]1CCCN2C(=O)CC[C@@H](C(N21)=O)NC(=O)C(NC)CC)S(=O)CCC1=CC=CC=C1 SVUWENNYDNCSJC-PDDQFZCSSA-N 0.000 claims 1
- ORFAJNZPFVYADB-KOEFYFSJSA-N n-[(4s,7s)-6,10-dioxo-4-(2-phenylethylsulfinylmethyl)-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepin-7-yl]-2-(methylamino)propanamide Chemical compound C([C@@H]1CCCN2C(=O)CC[C@@H](C(N21)=O)NC(=O)C(C)NC)S(=O)CCC1=CC=CC=C1 ORFAJNZPFVYADB-KOEFYFSJSA-N 0.000 claims 1
- QTBCWNLVCCSPAG-WMEOFMBSSA-N n-[(4s,7s)-6,10-dioxo-4-(2-phenylethylsulfonylmethyl)-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepin-7-yl]-2-(methylamino)butanamide Chemical compound C([C@@H]1CCCN2C(=O)CC[C@@H](C(N21)=O)NC(=O)C(NC)CC)S(=O)(=O)CCC1=CC=CC=C1 QTBCWNLVCCSPAG-WMEOFMBSSA-N 0.000 claims 1
- NHSIQVDIFCJCPO-MSYFUGIWSA-N n-[(4s,7s)-6,10-dioxo-4-(2-phenylethylsulfonylmethyl)-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepin-7-yl]-2-(methylamino)propanamide Chemical compound C([C@@H]1CCCN2C(=O)CC[C@@H](C(N21)=O)NC(=O)C(C)NC)S(=O)(=O)CCC1=CC=CC=C1 NHSIQVDIFCJCPO-MSYFUGIWSA-N 0.000 claims 1
- WTCMTMAVPBEDBQ-VNQANMTISA-N n-[(4s,7s)-6,10-dioxo-4-(3-phenoxyphenyl)-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepin-7-yl]-2-(methylamino)propanamide Chemical compound C=1C([C@@H]2CCCN3C(=O)CC[C@@H](C(N32)=O)NC(=O)C(C)NC)=CC=CC=1OC1=CC=CC=C1 WTCMTMAVPBEDBQ-VNQANMTISA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 229910003813 NRa Inorganic materials 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68863905P | 2005-06-08 | 2005-06-08 | |
| US60/688,639 | 2005-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007147959A true RU2007147959A (ru) | 2009-07-20 |
Family
ID=37052743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007147959/04A RU2007147959A (ru) | 2005-06-08 | 2006-06-06 | Органические соединения |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7989441B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1902065A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008545780A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080022092A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101193908B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006255084A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0611922A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2610396A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007015419A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007147959A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006133147A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| EA012810B1 (ru) | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Димерные ингибиторы ингибиторов белков апоптоза (iap) |
| AP2007004244A0 (en) | 2005-05-10 | 2007-12-31 | Intermune Inc | Method of modulating stress-activated protein kinase system |
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| AU2006308453B9 (en) | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
| WO2007101347A1 (en) * | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics, Inc. | composto de ligação de domìnio bir da iap |
| WO2008014229A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| MX2009000824A (es) | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| CA2670726A1 (en) | 2006-12-07 | 2008-06-19 | Novartis Ag | 6-oxo-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases |
| BRPI0720049A2 (pt) * | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
| JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法 |
| US8871111B2 (en) * | 2008-03-18 | 2014-10-28 | Ngk Insulators, Ltd. | Piezoelectric/electrostrictive ceramic composition |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| TW201249824A (en) | 2011-03-09 | 2012-12-16 | Glaxosmithkline Llc | Peptide deformylase inhibitors |
| JP2014528409A (ja) | 2011-09-30 | 2014-10-27 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ）） |
| US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| MX2015000362A (es) * | 2012-07-13 | 2015-04-14 | Hoffmann La Roche | Benzo(b)-azepin-2-onas antiproliferativas. |
| RU2015105561A (ru) | 2012-08-09 | 2016-09-27 | Ф. Хоффманн-Ля Рош Аг | Замещенные гетероазепиноны |
| BR112015004547A8 (pt) * | 2012-09-19 | 2018-01-23 | Hoffmann La Roche | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA2896577C (en) | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| KR20160030099A (ko) | 2013-06-25 | 2016-03-16 | 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 | 세포내 감염의 치료 방법 |
| CA2925084A1 (en) * | 2013-11-18 | 2015-05-21 | F. Hoffmann-La Roche Ag | Tetrahydro-benzodiazepinones |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| JP6768522B2 (ja) | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 |
| AR101479A1 (es) | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| EA038950B1 (ru) | 2016-05-19 | 2021-11-12 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения производных 6-алкинил-пиридина |
| LT3552017T (lt) * | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| CN106674228B (zh) * | 2016-12-09 | 2018-12-04 | 河南农业大学 | 多元杂环化合物及其制备方法和用途 |
| CA3063938A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US12678509B2 (en) | 2019-11-08 | 2026-07-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (IAP) protein antagonists |
| US20230056604A1 (en) | 2020-01-20 | 2023-02-23 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| RS66874B1 (sr) * | 2020-09-17 | 2025-06-30 | Novartis Ag | Jedinjenja i kompozicije kao inhibitori sppl2a |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| WO2025061058A1 (en) * | 2023-09-18 | 2025-03-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Novel compounds as iap antagonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521179A (en) * | 1991-04-18 | 1996-05-28 | Zeneca Limited | Heterocyclic amides |
| GB9207145D0 (en) * | 1991-04-18 | 1992-05-13 | Ici Plc | Heterocyclic amides |
| US5283241A (en) * | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5434261A (en) * | 1993-07-26 | 1995-07-18 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| JPH08225586A (ja) * | 1995-02-22 | 1996-09-03 | Fujisawa Pharmaceut Co Ltd | 新規リン酸誘導体、その製造法およびそれを含有する医薬組成物 |
| ATE310528T1 (de) * | 1996-09-12 | 2005-12-15 | Idun Pharmaceuticals Inc | Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie |
| US6423519B1 (en) * | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
| JP2005522430A (ja) | 2002-02-04 | 2005-07-28 | メルク エンド カムパニー インコーポレーテッド | グランザイムｂ阻害剤 |
| ATE400812T1 (de) * | 2003-02-07 | 2008-07-15 | Genentech Inc | Zusammensetzungen und verfahren für verstärkte apoptose |
| PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| BRPI0506883A (pt) * | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
| WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| BRPI0513310A (pt) | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
| US7652703B2 (en) * | 2004-07-12 | 2010-01-26 | Micron Technology, Inc. | Dual panel pixel readout in an imager |
| WO2006122408A1 (en) * | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
-
2006
- 2006-06-06 AU AU2006255084A patent/AU2006255084A1/en not_active Abandoned
- 2006-06-06 EP EP06760702A patent/EP1902065A2/en not_active Withdrawn
- 2006-06-06 KR KR1020077028586A patent/KR20080022092A/ko not_active Withdrawn
- 2006-06-06 US US11/916,887 patent/US7989441B2/en not_active Expired - Fee Related
- 2006-06-06 BR BRPI0611922-0A patent/BRPI0611922A2/pt not_active IP Right Cessation
- 2006-06-06 JP JP2008515811A patent/JP2008545780A/ja active Pending
- 2006-06-06 WO PCT/US2006/021850 patent/WO2006133147A2/en not_active Ceased
- 2006-06-06 MX MX2007015419A patent/MX2007015419A/es not_active Application Discontinuation
- 2006-06-06 RU RU2007147959/04A patent/RU2007147959A/ru not_active Application Discontinuation
- 2006-06-06 CA CA002610396A patent/CA2610396A1/en not_active Abandoned
- 2006-06-06 CN CN2006800202223A patent/CN101193908B/zh not_active Expired - Fee Related
-
2011
- 2011-06-15 US US13/161,166 patent/US20110281845A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101193908B (zh) | 2012-04-11 |
| WO2006133147A2 (en) | 2006-12-14 |
| JP2008545780A (ja) | 2008-12-18 |
| WO2006133147A3 (en) | 2007-05-03 |
| US20090069294A1 (en) | 2009-03-12 |
| CN101193908A (zh) | 2008-06-04 |
| EP1902065A2 (en) | 2008-03-26 |
| US7989441B2 (en) | 2011-08-02 |
| CA2610396A1 (en) | 2006-12-14 |
| BRPI0611922A2 (pt) | 2010-10-05 |
| US20110281845A1 (en) | 2011-11-17 |
| AU2006255084A1 (en) | 2006-12-14 |
| MX2007015419A (es) | 2008-02-21 |
| KR20080022092A (ko) | 2008-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008545780A5 (cg-RX-API-DMAC7.html) | ||
| KR101317661B1 (ko) | 이량체성 ｉａｐ 억제제 | |
| ES2684120T3 (es) | Combinación de un inhibidor de IAP y un taxano | |
| JP2011102312A (ja) | テトラペプチド類似体 | |
| JP2022536540A (ja) | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 | |
| JP5642777B2 (ja) | Ｉａｐ阻害剤 | |
| WO2020160295A1 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
| TW202444405A (zh) | G蛋白偶聯受體調節劑 | |
| BRPI0614515A2 (pt) | inibidores macrocìclicos de vìrus de hepatite c | |
| KR20070099527A (ko) | 유기 화합물의 조합물 | |
| BR9913646B1 (pt) | Tripeptídeos inibidores da hepatite C, composição farmacêutica compreendendo os mesmos, seu isômero óptico, uso e processo para sua preparação | |
| JP2005508311A (ja) | ｏ−フェニレンジアミンのＮ−モノアシル化誘導体、その六員複素環式アナログ、及び薬剤としてのそれらの使用 | |
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| JP2021152063A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0614654B1 (pt) | Inibidores macrocíclicos de vírus de hepatite c | |
| HUE034856T2 (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment of thromboembolic diseases | |
| JP2016506959A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0718798A2 (pt) | Inibidores macrocíclicos de vírus da hepatite c | |
| RU2006132463A (ru) | Антагонисты рецептора хемокина | |
| JP6642948B2 (ja) | リシンジンジパインの阻害剤 | |
| JP2008509187A5 (cg-RX-API-DMAC7.html) | ||
| JP2013540114A5 (cg-RX-API-DMAC7.html) | ||
| RU2009120229A (ru) | Производные хинуклидинола в качестве антагонистов мускариновых рецепторов | |
| BRPI0823522A2 (pt) | Uso de um composto derivado de ceramida | |
| CA2910593C (en) | Antimicrobial potentiators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20101014 |